Nitin Jain

Nitin Jain is a clinical investigator specializing in high-risk CLL, particularly TP53-mutated and del17p disease for which standard chemoimmunotherapy is largely ineffective. His research has characterized outcomes with BTK inhibitors and venetoclax combinations in this genomically high-risk subgroup. He leads early-phase clinical trials of novel agents and CAR-T cell therapies for CLL and explores strategies to achieve deep molecular remissions. His work on MRD monitoring and genomic evolution of CLL under targeted therapy pressure informs optimal treatment sequencing.